UCB 34714

Known as: UCB-34714, UCB34714 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
This final rule adopts without change an interim final rule with request for comments published in the Federal Register on May 12… (More)
Is this relevant?
2016
2016
  • Federal register
  • 2016
The Drug Enforcement Administration is placing the substance brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND AND PURPOSE Screening of 12,000 compounds for binding affinity to the synaptic vesicle protein 2A (SV2A), identified a… (More)
Is this relevant?
Review
2008
Review
2008
BACKGROUND Epilepsy is a neurological disorder with a worldwide prevalence estimated to be 0.5-1.0% of the population. Many… (More)
Is this relevant?
2007
2007
Brivaracetam (UCB 34714) is chemically related to levetiracetam (LEV, Keppra®). It possesses a binding affinity for the synaptic… (More)
Is this relevant?
Review
2007
Review
2007
Brivaracetam (UCB 34714) is chemically related to levetiracetam (LEV, Keppra). It possesses a binding affinity for the synaptic… (More)
Is this relevant?
Review
2006
Review
2006
In the last decade, 10 new antiepileptic drugs (AEDs) have been introduced that offer appreciable advantages in terms of their… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2005
Review
2005
Brivaracetam (UCB-34714), an orally active, high-affinity synaptic vesicle protein 2A ligand, is being developed by UCB for the… (More)
Is this relevant?
2004
2004
(S)-alpha-ethyl-2-oxopyrrolidine acetamide 2 (levetiracetam, Keppra, UCB S.A.), a structural analogue of piracetam, has recently… (More)
Is this relevant?
Review
2004
Review
2004
The Seventh Eilat Conference on New Antiepileptic Drugs (AEDs) (EILAT VII) took place in Villasimius, Sardinia, Italy from the… (More)
Is this relevant?